{"id":"W3029353272","doi":"10.1200/jco.2020.38.15_suppl.9623","title":"SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Amgen","keywords":"Medicine; Tremelimumab; Durvalumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Interim analysis; Progressive disease; Combination therapy; Cancer; Surgery; Immunotherapy; Gastroenterology; Chemotherapy; Clinical trial; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002006202,0.001402585,0.001400989,0.0003991655,0.0003424746,0.0007349135,0.0009061132,0.001135972,0.006267808],"category_scores_gemma":[0.0007059904,0.0005086884,0.0009912532,0.0003460106,0.0006731222,0.0006863392,0.0004134406,0.00204393,0.001483214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001037424,"about_ca_system_score_gemma":0.002725948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00140585,"about_ca_topic_score_gemma":0.005298157,"domain_scores_codex":[0.9996275,0.0001814478,0.00001956696,0.00004999044,0.00003875331,0.00008277312],"domain_scores_gemma":[0.9994759,0.00006452952,0.00008996177,0.00002828533,0.00003480705,0.0003065325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7177798,0.07380256,0.01448926,0.00166154,0.002198841,0.0005849707,0.0004957017,0.002480793,0.05128685,0.00064087,0.01589257,0.1186863],"study_design_scores_gemma":[0.6769583,0.2976556,0.01361728,0.00005254782,0.0005034059,0.0004913128,0.00006626906,0.001308246,0.003062373,0.0002245836,0.006034638,0.00002541815],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840466,0.001539529,0.0006078304,0.0005602449,0.0001201519,0.00676165,0.003719608,0.0001152747,0.002529061],"genre_scores_gemma":[0.9676108,0.00191508,0.002847908,0.001670356,0.0002026643,0.008466224,0.01069444,0.00005859856,0.006533858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006267808,"threshold_uncertainty_score":0.02096796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07130632551805678,"score_gpt":0.4141382348314257,"score_spread":0.3428319093133689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}